Truist Financial Issues Positive Forecast for Gilead Sciences (NASDAQ:GILD) Stock Price

Gilead Sciences (NASDAQ:GILD) had its price objective raised by Truist Financial from $140.00 to $145.00 in a research report released on Tuesday morning,Benzinga reports. The firm currently has a buy rating on the biopharmaceutical company’s stock.

Several other research firms have also issued reports on GILD. Mizuho lifted their price target on Gilead Sciences from $131.00 to $140.00 and gave the stock an “outperform” rating in a research report on Friday, November 21st. JPMorgan Chase & Co. lifted their target price on shares of Gilead Sciences from $145.00 to $150.00 and gave the stock an “overweight” rating in a report on Friday, October 31st. Wells Fargo & Company increased their price target on shares of Gilead Sciences from $145.00 to $150.00 and gave the company an “overweight” rating in a report on Wednesday, December 10th. Wolfe Research restated an “outperform” rating and issued a $150.00 price objective on shares of Gilead Sciences in a report on Monday, December 15th. Finally, Argus upped their price objective on Gilead Sciences from $130.00 to $135.00 and gave the company a “buy” rating in a research report on Tuesday, November 4th. One analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $135.36.

Gilead Sciences Price Performance

GILD stock opened at $140.97 on Tuesday. The company has a debt-to-equity ratio of 1.03, a quick ratio of 1.31 and a current ratio of 1.45. The firm has a 50 day moving average price of $124.53 and a 200-day moving average price of $119.10. Gilead Sciences has a 52-week low of $93.37 and a 52-week high of $141.71. The firm has a market capitalization of $174.90 billion, a price-to-earnings ratio of 21.86, a PEG ratio of 0.72 and a beta of 0.33.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Thursday, October 30th. The biopharmaceutical company reported $2.47 earnings per share for the quarter, topping the consensus estimate of $2.16 by $0.31. Gilead Sciences had a return on equity of 51.86% and a net margin of 27.88%.The company had revenue of $7.77 billion for the quarter, compared to the consensus estimate of $7.42 billion. During the same quarter in the prior year, the business posted $2.02 EPS. The firm’s quarterly revenue was up 3.0% compared to the same quarter last year. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. Equities research analysts forecast that Gilead Sciences will post 7.95 EPS for the current fiscal year.

Insiders Place Their Bets

In other Gilead Sciences news, Director Kelly A. Kramer sold 2,805 shares of the business’s stock in a transaction on Friday, November 28th. The shares were sold at an average price of $127.10, for a total transaction of $356,515.50. Following the completion of the sale, the director directly owned 1,339 shares in the company, valued at approximately $170,186.90. The trade was a 67.69% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Johanna Mercier sold 3,000 shares of the firm’s stock in a transaction on Thursday, January 15th. The stock was sold at an average price of $124.31, for a total value of $372,930.00. Following the completion of the transaction, the insider owned 103,221 shares in the company, valued at approximately $12,831,402.51. This trade represents a 2.82% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 247,397 shares of company stock worth $31,986,612 in the last 90 days. Insiders own 0.27% of the company’s stock.

Institutional Investors Weigh In On Gilead Sciences

Several hedge funds and other institutional investors have recently made changes to their positions in GILD. GoalVest Advisory LLC grew its position in Gilead Sciences by 7,566.7% during the second quarter. GoalVest Advisory LLC now owns 230 shares of the biopharmaceutical company’s stock valued at $26,000 after buying an additional 227 shares during the period. Corundum Trust Company INC purchased a new position in shares of Gilead Sciences during the 3rd quarter worth $26,000. Financial Consulate Inc. grew its position in shares of Gilead Sciences by 85.8% during the 4th quarter. Financial Consulate Inc. now owns 236 shares of the biopharmaceutical company’s stock valued at $29,000 after acquiring an additional 109 shares during the period. Harbor Asset Planning Inc. purchased a new stake in shares of Gilead Sciences in the 2nd quarter worth $27,000. Finally, BOCHK Asset Management Ltd purchased a new stake in shares of Gilead Sciences in the 4th quarter worth $31,000. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Trending Headlines about Gilead Sciences

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Multiple major banks raised price targets and kept bullish ratings, increasing investor conviction that upside remains (Citigroup to $156, UBS to $155, BMO to $150, Truist to $145). Analysts cited in these notes are maintaining buy/outperform views, which supports demand for GILD. Citigroup price‑target note UBS/Truist coverage BMO note
• Positive Sentiment: Press reports note GILD reached a new 1‑year high on the analyst upgrade momentum — a technical trigger that can attract momentum buyers and ETFs. AmericanBankingNews article
• Neutral Sentiment: Company fundamentals and guidance remain supportive: Gilead’s most recent quarter beat EPS and revenue expectations and management set FY2025 EPS guidance (8.05–8.25), which underpins analyst optimism but is not new today. (See analyst consensus and company metrics for context.) MarketBeat company summary
• Negative Sentiment: GILD’s CEO, Daniel Patrick O’Day, sold 115,640 shares (avg $135) in a disclosed transaction — a large insider sale that may prompt concern or profit‑taking among some investors despite his remaining sizeable stake. The SEC filing and trade detail are public. SEC Form 4 (insider sale) InsiderTrades report

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.